RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Brainstorm Cell Therapeutics Stock

Brainstorm Cell Therapeutics Market capitalization 2024

Brainstorm Cell Therapeutics Market capitalization

14.67 M USD

Ticker

BCLI

ISIN

US10501E2019

WKN

A12BXW

In 2024, Brainstorm Cell Therapeutics's market cap stood at 14.67 M USD, a -80.02% increase from the 73.4 M USD market cap in the previous year.

The Brainstorm Cell Therapeutics Market capitalization history

YEARMarket Capitalization (undefined USD)
202368.58
2022110.45
2021147.11
2020263.13
201984.77
201873.03
201774.59
201644.76
201564.57
201455.87
201333.69
201232.85
201138.51
201021.95
20099.41
200815.04
200717.65
20069.27
200531.23

Brainstorm Cell Therapeutics Aktienanalyse

What does Brainstorm Cell Therapeutics do?

Brainstorm Cell Therapeutics Inc is an emerging biotech company based in New York City that focuses on developing novel therapies for the treatment of neurodegenerative diseases. The company was founded in 2002 by a team of leading scientists and experts in the field of stem cell research. Their goal was to advance the development of treatment options for diseases such as ALS (Amyotrophic Lateral Sclerosis), Multiple Sclerosis, and Parkinson's through innovative approaches to stem cell therapy. Brainstorm Cell Therapeutics' business model is based on the unique property of stem cells to differentiate into a variety of cell types and regenerate damaged tissue. The company harnesses this ability to develop tailored stem cell therapies that are customized to meet the specific needs of each patient. By utilizing the potential of stem cells to repair tissue damage and support the body's own healing process. The company is divided into two divisions: therapeutics and diagnostics. The therapeutics division is the core area, focusing on the development of stem cell therapies for the treatment of ALS, Multiple Sclerosis, Parkinson's, and other diseases. The company has developed an approach using autologous stem cells, where stem cells are extracted from the patient's own body to minimize the risk of rejection reactions. The company has already reached Phase II clinical trials and has demonstrated promising results from this innovative technology stem cell therapy for the treatment of ALS, as well as MS and Parkinson's. The diagnostics division of Brainstorm Cell Therapeutics focuses on the development of diagnostic tests to aid physicians in diagnosing patients with neurodegenerative diseases more quickly and accurately. One of the current developments is the NurOwn ALS diagnostic test, which is based on the impact of ALS on the patient's immune system. One of Brainstorm Cell Therapeutics' most well-known products is "NurOwn." This stem cell therapy product is provided to ALS patients. The product utilizes the patient's autologous stem cells to slow the progression of the disease and promote the growth of healthy tissue. It is a personalized therapy, tailored to the specific needs of each patient. The company has already conducted various clinical trials with NurOwn and achieved promising results. Brainstorm Cell Therapeutics is an innovative biotech company focused on the development of stem cell therapies for the treatment of neurodegenerative diseases. The company has already achieved promising results with its therapies and plans to further improve its product range. With a strong scientific team and innovative business model, it is well-positioned to play a leading role in the development of therapies for the treatment of neurodegeneration in the future. Brainstorm Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Brainstorm Cell Therapeutics's Market Capitalization

Brainstorm Cell Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Brainstorm Cell Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Brainstorm Cell Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Brainstorm Cell Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Brainstorm Cell Therapeutics stock

What is the current Brainstorm Cell Therapeutics market capitalization?

The current market capitalization of Brainstorm Cell Therapeutics is 14.67 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Brainstorm Cell Therapeutics.

How has the market capitalization of Brainstorm Cell Therapeutics developed in recent years?

The market capitalization of Brainstorm Cell Therapeutics has increased/decreased by -80.02% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Brainstorm Cell Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Brainstorm Cell Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Brainstorm Cell Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Brainstorm Cell Therapeutics pay?

Over the past 12 months, Brainstorm Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Brainstorm Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Brainstorm Cell Therapeutics?

The current dividend yield of Brainstorm Cell Therapeutics is .

When does Brainstorm Cell Therapeutics pay dividends?

Brainstorm Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Brainstorm Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Brainstorm Cell Therapeutics located?

Brainstorm Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Brainstorm Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Brainstorm Cell Therapeutics from 8/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/17/2024.

When did Brainstorm Cell Therapeutics pay the last dividend?

The last dividend was paid out on 8/17/2024.

What was the dividend of Brainstorm Cell Therapeutics in the year 2023?

In the year 2023, Brainstorm Cell Therapeutics distributed 0 USD as dividends.

In which currency does Brainstorm Cell Therapeutics pay out the dividend?

The dividends of Brainstorm Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Brainstorm Cell Therapeutics

Our stock analysis for Brainstorm Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brainstorm Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.